Health Care [ 11/12 ] | Biotechnology [ 55/73 ]
NASDAQ | Common Stock
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 25 | -0.34 Increased by +78.88% | -0.33 Decreased by -3.82% |
| Mar 3, 25 | -0.27 Decreased by -9.64% | -0.36 Increased by +23.16% |
| Nov 13, 24 | -0.34 Decreased by -21.43% | -0.44 Increased by +23.30% |
| Aug 15, 24 | -1.83 Decreased by -577.78% | -0.87 Decreased by -110.34% |
| May 14, 24 | -1.61 Decreased by -631.82% | -2.00 Increased by +19.50% |
| Feb 27, 24 | -0.25 Decreased by -19.05% | -0.21 Decreased by -19.05% |
| Nov 9, 23 | -0.28 Decreased by -12.00% | -0.22 Decreased by -27.27% |
| Aug 11, 23 | -0.27 Increased by 0.00% | -0.25 Decreased by -8.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 381.00 K Decreased by -30.47% | -5.01 M Decreased by -23.48% | Decreased by -1.32 K% Decreased by -77.61% |
| Dec 31, 24 | 603.00 K Increased by +857.14% | -4.08 M Increased by +32.30% | Decreased by -676.78% Increased by +92.93% |
| Sep 30, 24 | 773.00 K Increased by +415.33% | -4.42 M Increased by +25.15% | Decreased by -571.67% Increased by +85.48% |
| Jun 30, 24 | 468.00 K Increased by +115.67% | -3.41 M Increased by +39.40% | Decreased by -729.27% Increased by +71.90% |
| Mar 31, 24 | 548.00 K Increased by +96.42% | -4.06 M Increased by +11.36% | Decreased by -740.51% Increased by +54.87% |
| Dec 31, 23 | 63.00 K Decreased by -47.93% | -6.03 M Decreased by -59.81% | Decreased by -9.57 K% Decreased by -206.93% |
| Sep 30, 23 | 150.00 K Decreased by -43.40% | -5.90 M Decreased by -11.38% | Decreased by -3.94 K% Decreased by -96.76% |
| Jun 30, 23 | 217.00 K Decreased by -53.43% | -5.63 M Increased by +19.85% | Decreased by -2.60 K% Decreased by -72.12% |